Recent developments in the discovery of protein kinase inhibitors from the urea class

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 5, 2004, Pages 600-616

  Dumas, Jacques ^a   Smith, Roger A ^a   Lowinger, Timothy B ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Angiogenesis; Cancer; Cell cycle; Inflammation; Kinase; Urea

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; CYTOTOXIC AGENT; DORAMAPIMOD; DOXORUBICIN; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; KRN 951; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE INHIBITOR; SORAFENIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER; CLINICAL TRIAL; CROHN DISEASE; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERANCE; HUMAN; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; UREA;

EID: 4944239434     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Zvelebil M: STI-751 Novartis AG. Curr Opin Oncol Endocr Metab Invest Drugs (2000) 2(1):74-82.
2. Baselga J, Averbuch SO: ZD1839 ('Iressa') as an anticancer agent. Drugs (2000) 60(Suppl 1):33-40.
3. Sausville EA: Protein kinase antagonists: Interim challenges and issues. Anticancer Drug Des (2000) 15(1):1-2.
4. Dumas J: Protein kinase inhibitors from the urea class. Curr Opin Drug Discovery Dev (2002) 5(5):718-727. • Most of the references pertaining to urea-based inhibitors prior to 2002 have been reviewed in this article, and are omitted in the present review.
5. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C et al. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem (2002) 45(14):2994-3008. •• An interesting perspective on the design and discovery of BIRB-796.
6. Pargellis C, Tong L, Churchill L, Cirillo P, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9(4):268-272. • The first disclosure of a urea-based inhibitor inducing a DFG flip.
7. Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, Hickey E, Kroe RR, Madwed J, Moriak M, Nelson R, Pargellis CA et al. Structure-activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl- 2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J Med Chem (2003) 46(22):4676-4686. •• An interesting perspective on the design and discovery of BIRB-796, including the optimization of drug-like properties.
8. Regan J, Pargellis CA, Cirillo PF, Gilmore T, Hickey ER, Peet GW, Proto A, Swinamer A, Moss N: The kinetics of binding to p38 MAP kinase by analogues of BIRB 796. Bioorg Med Chem Lett (2003) 13(18):3101-3104.
9. Kroe RR, Regan J, Proto A, Peet GW, Roy T, Landro LD, Fuschetto NG, Pargellis CA, Ingraham RH: Thermal denaturation: A method to rank slow binding, high-affinity p38α MAP kinase inhibitors. J Med Chem (2003) 46(22):4669-4675.
10. Pargellis CA, Forest MA, Madwed JB, Moss N, Raymond E, Schwartz R, Souza D, Torcellini C, Weldon SM, Zimmitti C, Regan J: A novel series of p38 MAP kinase inhibitors: Development of a new clinical candidate BIRB 796 BS. 223rd ACS National Meeting, Orlando, FL, USA (2002):MEDI-020.
11. Moss N, Regan J, Pargellis C, Madwed J, Tong L, Cirillo P, Hickey E, Gilmore T: Pyrazole urea based p38 inhibitors: Discovery of a clinical candidate. 223rd ACS National Meeting, Orlando, FL, USA (2002):MEDI-262.
12. Swinamer AD, Capolino A, Cirillo PF, Gilmore T, Graham A, Hickey E, Moriak M, Madwed J, Moss N, Nelson R, Pargellis C et al: Synthesis and biological evaluation of BIRB 796 analogs as potent inhibitors of p38 MAP kinase. 224th ACS National Meeting, Boston, MA, USA (2002):MEDI-303.
13. Cirillo PF, Capolino A, Gilmore T, Graham A, Hao MH, Hickey E, Kroe R, Moriak M, Madwed J, Moss N, Nelson R et al. Biological evaluation of BIRB 796 analogs as potent inhibitors of p38 MAP. 31st Northeast Regional Meeting of the ACS, Saratoga Springs, NY, USA (2003):Abs 60.
14. Moss N: Binding modes of known classes of p38 MAP kinase inhibitors. 226th ACS National Meeting, New York, NY, USA (2003):COMP-093.
15. Cirillo PF, Pargellis C, Regan J: The non-diaryl heterocycle classes pf p38 MAP kinase inhibitors. Curr Top Med Chem (2002) 2(9):1021-1035.
16. Pargellis C, Regan J: Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Invest Drugs (2003) 4(5):566-571.
17. Polmar SH, Yong C-L, Staehle H, Wood CC, Gupta A: Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers. J Allergy Clin Immunol (2002) 109(No 1 Pt 2):Abs 157.
18. Gupta A, Yong C-L, Madwed JB, Staehle H, Wood CC: Safety, pharmacokinetics and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males a placebo-controlled, randomised study, double blinded at each dose level. J Allergy Clin Immunol (2002) 109(No 1 Pt 2):Abs 158.
19. Wood CC, Yong C-L, Madwed JB, Gupta A: Safety, pharmacokinetics and pharmacodynamics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days. J Allergy Clin Immunol (2002) 109(No 1 Pt 2):Abs 993.
20. Evans R: Anti-arthritic agents - SMi conference. IDrugs (2003) 6(6):548-551.
21. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJ et al: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol (2002) 168(8):4070-4077. • Proof-of-concept studies with BIRB-796.
22. Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, Peppelenbosch MP, van der Poll T: Inhibition of coagulation, fibrinolysis and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human edotoxemia. Blood (2003) 101(11):4446-4448.
23. Van den Blink B, Branger J, Weijer S, Gupta A, van Deventer SJ, Peppelenbosch MP, van der Poll T: p38 Mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia. J Clin Immunol (2004) 24(1):37-41.
24. Lowinger TB, Riedl B, Dumas J, Smith RA: Design and discovery of small molecules targeting Raf-1 kinase. Curr Pharm Des (2002) 8(25):2269-2278.
25. Wilhelm S, Chien DS: BAY 43-9006: Preclinical data. Curr Pharm Des (2002) 8(25):2255-2257.
26. Bankston D, Dumas J, Natero R, Riedl B, Monahan MK, Sibley R: A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer. Org Process Res Dev (2002) 6(6):777-781.
27. Sorbera LA, Castañer J, Bozzo J, Leeson PA: BAY-43-9006. Oncolytic, Raf kinase inhibitor. Drugs Future (2002) 27(12):1141-1147.
28. Bollag G, Freeman S, Lyons JF, Post LE: Raf pathway inhibitors in oncology. Curr Opin Invest Drugs (2003) 4(12):1436-1441.
29. Lee JT, McCubrey JA: BAY-43-8006 (Bayer/Onyx). Curr Opin Invest Drugs (2003) 4(6):757-763.
30. Hotte SJ, Hirte HW: BAY 43-9006: Early clinical data in patients with advanced solid malignancies. Curr Pharm Des (2002) 8(25):2249-2253.
31. DeGrendele H: Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. Clin Colorectal Cancer (2003) 3(1):16-18.
32. Wilhelm S, Carter C, Tang LY, Rong H, Chen C, Zhang X, McHugh M, Wilkie D, McNabola M, Rowley B, Henderson A et al: BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, USA (2003):A78. • Important information pertaining to the kinase profile and mechanism of action of BAY-43-9006. A paper related to the same subject is currently in press.
33. Khire UR, Bankston D, Barbosa J, Brittelli DR, Caringal Y, Carlson R, Dumas J, Gane T, Heald SL, Hibner B, Johnson JS et al: Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent. Bioorg Med Chem Lett (2004) 14(3):783-786.
34. Mross K, Steinbild S, Baas F, Reil M, Buss P, Mersmann S, Voliotis D, Schwartz B, Brendel E: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharm Ther (2003) 41(12):618-619.
35. Siu LL, Awada A, Takimoto CH, Moore MJ, Piccart M, Fiander W, Lathia C, Petrensiuc O: Phase I study of oral Raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors. 39th ASCO Meeting, Chicago, IL, USA (2003):Abs 828.
36. Richly H, Kupsch P, Passage K, Grugert M, Hilger RA, Kredke S, Voliotis D, Scheulen ME, Seeber S, Strumberg D: A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther (2003) 41 (12):620-621.
37. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J et al: Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res (2003) 63(21):7301-7309. •• Detailed pharmacological profile of CP-547632.
38. Tolcher AW, O'Leary JJ, DeBono JS, Caulkins JD, Molpus K, Sutula K, Ferrante KJ, Gualberto A, Noe DA, Huberman M, Rowinsky EK et al: A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. 38th ASCO Meeting, Orlando, FL, USA (2002):Abs 334.
39. Shen J, La Rosee P, Griswold I, Heinrich MC, Braziel R, McGreevey L, Haley A, Giese N, Druker BJ, Deininger MW: Effects of MLN518 (CT53518), a dual Flt3 and Kit inhibitor, on normal and malignant hematopoiesis. Blood (2003) 102(11):Abs 476.
40. Heinrich MC, Yee KW, Giese NA, Schittenhelm M: MLN518, a potent Flt3 inhibitor, displays synergistic effects with cytarabine and daunorubicin on Flt3 ITD leukemia cell lines. Blood (2003) 102(11):Abs 330.
41. Yu J-C, Apatira M, Li J, Sullivan C, Hwang S, Lokker N, Giese NA: Mechanisms of cellular resistance to MLN518 (CT53518), a Flt3 antagonist in clinical development for the treatment of acute myelogenous leukemia (AML). Blood (2003) 102(11):Abs 2180.
42. Lokker NA, Sullivan CM, Yazar B, Iartchouk N, Hwang S, Giese NA: Transcriptional profiling of Flt3 ITD-positive leukemia cells treated with the Flt3 antagonist MLN518 (CT53518) identifies signaling pathways mediating cellular proliferation and survival. Blood (2003) 102(11):Abs 1334.
43. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D et al: CT53518, a novel selective Flt3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1(5):421-432.
44. Matsuno K, Ichimura M, Nakajima T, Tahara K, Fujiwara S, Kase H, Ushiki J, Giese NA, Pandey A, Scarborough RM, Lokker NA et al: Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. J Med Chem (2002) 45(14):3057-3066. •• This paper, along with references [45*•], [46••] and [47••], provides detailed SAR information on quinazoline-based ureas.
45. Matsuno K, Nakajima T, Ichimura M, Giese NA, Yu JC, Lokker NA, Ushiki J, Ide S, Oda S, Nomoto Y: Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure-activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem (2002) 45(20):4513-4523. •• This paper, along with references [44••], [46••] and [47••], provides detailed SAR information on quinazoline-based ureas.
46. Matsuno K, Ushiki J, Seichi T, Ichimura M, Giese NA, Yu JC, Takahashi S, Oda S, Nomoto Y: Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem (2003) 46(23):4910-4925. •• This paper, along with references [44••], [45••] and [47••], provides detailed SAR information on quinazoline-based ureas.
47. Matsuno K, Seichi T, Nakajima T, Ichimura M, Giese NA, Yu JC, Oda S, Nomoto Y: Potent and selective inhibitors of PDGF receptor phosphorylation. Part 4: Structure-activity relationships for substituents on the quinazoline moiety of of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7- dimethoxyquinazoline derivatives. Bioorg Med Chem Lett (2003) 13(18):3001-3004. •• This paper, along with references [44••], [45••] and [46••], provides detailed SAR information on quinazoline-based ureas.
48. Yu JC, Lokker NA, Hollenbach S, Apatira M, Li J, Betz A, Sedlock D, Oda S, Nomoto Y, Matsuno K, Ide S et al: Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharm Exp Ther (2001) 298(3):1172-1178. • Pharmacological profite of CT-52923.
49. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese N, Scarborough RM: Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem (2002) 45(17):3772-3793. •• Optimization program leading to MLN-518. Includes important details on drug-like property optimization in the kinase field.
50. Burchat AF, Calderwood DJ, Friedman MM, Hirst GC, Li B, Rafferty P, Ritter K, Skinner BS: Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Biorg Med Chem Lett (2002) 12(12):1687-1690.
51. Kubo K, Ohyama S, Shimizu T, Takami A, Murooka H, Nishitoba T, Kato S, Yagi M, Kobayashi Y, Iinuma N, Isoe T et al: Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg Med Chem (2003) 11(23):5117-5133.
52. Kubo K, Shimizu T, Ohyama S, Murooka H, Nishitoba T, Kato S, Kobayashi Y, Yagi M, Isoe T, Nakamura K, Osawa T et al: A novel series of 4-phenoxyquinolines: Potent and highly selective inhibitors of PDGF receptor autophosphorylation. Bioorg Med Chem Lett (1997) 7(23):2935-2940. • One of the first disclosures of diaryl ureas as kinase inhibitors.
53. Yagi M, Kato S, Kobayashi Y, Kobayashi N, Iinuma N, Nakamura K, Kubo K, Ohyama S, Murooka H, Shimizu T, Hishitoba T et al: Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. Gen Pharmacol (1998) 31(5):765-773.
54. Shimizu T, Fujiwara Y, Osawa T, Sakai T, Kubo K, Kubo K, Nishitoba T, Kimura K, Senga T Murooka H, Iwai A et al: Orally active anti-proliferation agents: Novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. Bioorg Med Chem Lett (2004) 14(4):875-879.
55. Nakamura K, Taguchi E, Takahashi K, Kamishohara M, Miura T, Shibuya M, Isoe T: In vitro selectivity and potency of KRN951, a novel inhibitor of VEGF receptor tyrosine kinases. 95th AACR Meeting, Orlando, FL, USA (2004):Abs 2571.
56. Taguchi E, Nakamura K, Takahashi K, Kamishohara M, Miura T, Shibuya M, Isoe T: A novel orally active inhibitor of VEGF receptor tyrosine kinases KRN951: Anti-angiogenic and anti-tumor activities against human solid tumors. 95th AACR Meeting, Orlando, FL, USA (2004):Abs 2575.
57. Ohno H, Kubo K, Murooka H Kobayashi Y, Hirai M, Nishitoba T, Yoneda T, Isoe T: Oral administration of Ki20227, a novel c-Fms tyrosine kinase inhibitor, suppresses osteolytic bone metastasis. 95th AACR Meeting, Orlando, FL, USA (2004):Abs 4642.
58. Yamamoto Y, Watanabe T, Miyazaki K Tsuruoka A, Wakabayashi T, Asada M: E7080, an oral multitargeted tyrosine kinase inhibitor, has direct anti-tumor efficacy via inhibition of Kit signaling in small cell lung cancer. 95th AACR Meeting, Orlando, FL, USA (2004):Abs 4636.
59. Baxter A, Brough S, Cooper A, Floettmann E, Foster S, Harding C, Kettle J, McInally T, Martin C, Mobbs M, Needham M et al: Hit-to-lead studies: The discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg Med Chem Lett (2004) 14(11):2817-2822.
60. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K, Iwama T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Iwasawa Y et al: Structure-based generation of a new class of potent CDK4 inhibitors: New de novo design strategy and library design. J Med Chem (2001) 44(26):4615-4627.
61. Larsen SD, Stachew CF, Clare PM, Cubbage JW, Leach KL: A catch and release strategy for the combinatorial synthesis of 4-acylamino-1,3-thiazoles as potential CDK5 inhibitors. Bioorg Med Chem Lett (2003) 13(20):3491-3495.
62. Wan PT, Gamett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the Raf-ERK signaling pathway by oncogenic mutations of b-Raf. Cell (2004) 116(6).855-867.
63. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 62(15):4236-4243.
64. Schindler T, Bommann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science (2000) 289(5486):1938-1942. • Early example of a protein kinase inhibitor inducing a DFG flip.
65. Manley PW, Furet P, Bold G, Brueggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A, Kruger M et al: Anthranilic acid amides: A novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem (2002) 45(26):5687-5693.
66. Manley PW, Bold G, Fendrich G, Furet P, Mestan J, Meyer T, Meyhack B, Stark W, Strauss A, Wood J: Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Cell Mol Biol Lett (2003) 8(2A):532-533.
67. Furet P, Bold G, Hofmann F, Manley P, Meyer T, Altmann KH: Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg Med Chem Lett (2003) 13(18):2967-2971. • Interesting insights on the design of anthranilamide-based VEGFR-2 inhibitors.
68. Ikuta M, Kamata K, Fukazawa K, Honma T, Machida T, Hirai H, Suzuki-Takahashi I, Hayama T, Nishimura S: Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J Biol Chem (2001) 276(29):27548-27554.
69. Lck inhibitor BMS-243117. Bioorg Med Chem Lett (2003) 13(13):2145-2149.
70. Lck inhibitors. Bioorg Med Chem Lett (2003) 13(15):2587-2590.
71. SUGEN INC (Tang PC, McMahon G): Novel urea and thiourea-type compounds. WO-09640673 (1996).
72. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Goldberg DR, Hammach A, Moss N, Mueller K, Regan JR): 1,4-Disubstituted benzofused compounds. WO-02083628 (2002).
73. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Breitfelder S, Cirillo PF, Regan JR): Compounds useful as anti-inflammatory agents. WO-02083642 (2002).
74. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Goldberg DR, Hammach A, Moss N, Regan JR): Diarylurea derivatives useful as anti-inflammatory agents. WO-02092576 (2002).
75. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Kamhi V, Regan JR, Tsang M): Carbamate and oxamide compounds as inhibitors of cytokine production. WO-02096876 (2002).
76. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Hickey ER): 1,4-Disubstituted benzo-fused cycloalkyl urea compounds. WO-02098869 (2002).
77. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Hammach A, Regan JR): 1,4-Disubstituted benzo-fused ureas as cytokine inhibitors. WO-03032989 (2003).
78. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Regan JR, Hammach A): 1,4-Disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases. WO-03072569 (2003).
79. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cirillo PF, Hammach A, Kamhi V, Moss N, Riska PS, Pargellis C): Fluorinated phenylnaphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes. WO-2004014870 (2004).
80. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cappola ML, Gereg GW, Way S): Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)- 3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea. WO-00207772 (2002).
81. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Cappola ML, Way SL): Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4- yl-ethoxy)-naphthalen-1-yl]urea and a cyclodextrin. WO-03015828 (2003).
82. BOEHRINGER INGELHEIM PHARMACEUTICALS GMBH & Co KG (Jung B): p38 Kinase inhibitors for treating mucus hypersecretion. WO-03084503 (2003).
83. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Grob PM, Madwed JB, Pargellis C, Yong C-L): Method for administration of BIRB 796 BS. WO-03049742 (2003).
84. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Tan Z, Song JJ): Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents. WO-02066442 (2002).
85. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Wood CC, Van Der Poll T): Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors. WO-2004016267 (2004).
86. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Moss N, Regan JR): Methods of treating cytokine mediated diseases. WO-03005999 (2003).
87. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Moss N, Regan JR): Methods of treating cytokine-mediated diseases. WO-03022273 (2003).
88. BOEHRINGER INGELHEIM PHARMACEUTICALS GMBH & CO KG (Jung B, Pairet M, Pieper MP, Reiser HC): New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors. WO-03084539 (2003).
89. BOEHRINGER INGELHEIM PHARMACEUTICALS GMBH & Co KG (Pairet M, Meade CJM, Pieper MP): New pharmaceutical compositions based on novel anticholinergics and P38 kinase inhibitors. WO-2004004725 (2004).
90. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Simianer S, Bilbault P, Cappola ML, Way SL): Combination therapy with p38 (MAP kinase inhibitors and their pharmaceutical compositions. WO-2004014387 (2004).
91. BAYER CORP (Dumas J, Scott WJ, Elting J, Hatoum-Makdad H): Aryl ureas with Raf kinase and angiogenesis inhibiting activity. WO-03068223 (2003).
92. ASTEX TECHNOLOGY LTD (Murray CW, Hartshorn MJ, Frederickson M, Congreve MS, Padova A, Woodhead SJ, Gill AL, Woodhead AJ): 3-[(Hetero) arylmethoxy] pyridines and their analogues as p38 map kinase inhibitors. WO-2004004720 (2004).
93. BAYER CORP (Riedl B, Dumas J, Khire U, Lowinger TB, Scott WJ, Smith RA, Wood JE, Monahan MK, Natero R, Renick J, Sibley R): ω-Carboxyaryl substituted diphenyl ureas as Raf kinase inhibitors. WO-00042012 (2000).
94. BAYER CORP (Dumas J, Scott WJ, Elting J, Hatoum-Mokdad, H): Aryl ureas with angiogenesis inhibiting activity. WO-03068228 (2003).
95. BAYER CORP (Dumas J, Riedl B, Khire U, Wood JE, Sibley RN, Monahan MK, Renick J, Gunn DE, Lowinger TB, Scott WJ, Smith RA): Inhibition of Raf kinase using quinolyl, isoquinolyl or pyridyl ureas. WO-02062763 (2002).
96. BAYER CORP (Dumas J, Riedl B, Khire U, Sibley RN, Hatoum-Mokdad H, Monahan MK, Gunn DE, Lowinger TB, Scott WJ, Smith RA, Wood JE): Inhibition of Raf kinase using quinolyl, isoquinolyl or pyridyl ureas. WO-02085857 (2002).
97. BAYER CORP (Dumas J, Scott WJ, Riedl B): Pyridine, quinoline or isoquinoline N-oxides as kinase inhibitors. WO-03068229 (2003).
98. BAYER CORP (Dumas J, Scott WJ, Chien DS, Lee W, Bjorge S, Musza L, Nassar A, Riedl B): Aryl ureas as kinase inhibitors. WO-03068746 (2003).
99. MERCK PATENT GMBH (Buchstaller HP, Wiesner M, Schadt O, Amendt C, Zenke F, Sirrenberg C, Grell M, Finsinger D): Methylene urea derivatives. WO-2004037789 (2004).
100. SMITHKLINE BEECHAM CORP (Adams JL, Bryan DL, Kasparec J, King FD, Takle AK, Wilson DM, Goodman SN): Chemical compounds. WO-2004043379 (2004).
101. NOVARTIS PHARMA GMBH (Floersheimer, A, Furel P, Manley PW, Bold G, Boss E, Guagnano V, Vaupel A): Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases. WO-03099771 (2003).
102. BAYER CORP (Carter CA, Dumas J, Gibson N, Hibner B, Humphrey RW, Trail P, Vincent P, Zhai Y, Riedl B, Khire U, Lowinger TB et al): Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers. WO-03047579 (2003).
103. PFIZER PRODUCTS INC (Kwan TA, Lagreca SD, Lippa BS, Morris J, Wessel MD): Isothiazole derivatives useful as anticancer agents. WO-2004011461 (2004).
104. KYOWA HAKKO KOGYO CO LTD (Matsuno K, Ichimura M, Nomoto Y, Fujiwara S, Ide S, Tsukuda E, Irie J, Oda S): Nitrogenous heterocyclic compounds. WO-09814431 (1998).
105. COR THERAPEUTICS INC/KYOWA HAKKO KOGYO CO LTD (Pandey A, Scarborough RM, Matsuno K, Ichimura M, Nomoto Y, Fujiwara S, Ide S, Tsukuda E, Irie J, Oda S): Nitrogenous heterocyclic compounds. WO-00216362 (2002).
106. COR THERAPEUTICS INC/KYOWA HAKKO KOGYO Co LTD (Pandey A, Scarborough RM, Matsuno K, Ichimura M, Nomoto Y, Fujiwara S, Ide S, Tsukuda E, Irie J, Oda S): Nitrogenous heterocyclic compounds. WO-00216360 (2002).
107. COR THERAPEUTICS INC/KYOWA HAKKO KOGYO Co LTD (Pandey A, Scarborough RM, Matsuno K, Ichimura M, Nomoto Y, Fujiwara S, Ide S, Tsukuda E, Irie J, Oda S): Quinazoline derivatives as kinase inhibitors. WO-00216351 (2002).
108. COR THERAPEUTICS INC (Kanter J, Pandey A, Robinson J, Scarborough RM): Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof. WO-00236587 (2002).
109. ABBOTT LABORATORIES (Michaleides MR, Dai Y, Davidsen SK, Frey RR, Guo Y, Ji Z, Curtin M): Thiopyrimidine and isothiazolopyrimidine kinase inhibitors. WO-03080625 (2003).
110. ABBOTT LABORATORIES (Hirst GC, Arnold LD, Burchat A, Wishart N, Calderwood D, Wada CK, Michaleides MR, Ji Z, Muckey M): Kinase inhibitors. WO-03080064 (2003).
111. SMITHKLINE BEECHAM CORP (Adams JL, Kasparec J, Silva D, Yuan CCK): Chemical compounds. WO-03029209 (2003).
112. SMITHKLINE BEECHAM CORP (Adams JL, Kasparec J, Silva D): Chemical compounds. WO-03072541 (2003).
113. SMITHKLINE BEECHAM CORP (Adams JL, Silva D): Chemical compounds. WO-03027093 (2003).
114. KIRIN BEER KK (Miwa A, Yoshino T, Osawa T, Sakai T, Shimizu T, Fujiwara Y): Quinoline or quinazoline derivatives inhibiting autophosphorylation of fibroblast growth factor receptors. WO-03033472 (2003).
115. KIRIN BEER KK (Kubo K, Sakai T, Nagao R, Fujiwara Y, Isoe T, Hasegawa K): Quinoline derivative having azolyl group and quinazoline derivative. WO-02088110 (2002).
116. KIRIN BEER KK (Kubo K, Ohyama S, Shimizu T, Nishitoba T, Kato S, Murooka M, Kobayashi Y): Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same. WO-09717329 (1997).
117. KIRIN BEER KK (Sakai T, Senga T, Furuta T Miwa A): Quinoline and quinazoline derivatives and drugs containing the same. WO-00147890 (2001).
118. KIRIN BEER KK (Kubo K, Fujiwara Y, Isoe T): Quinoline derivatives and quinazoline derivatives. WO-00043366 (2000).
119. KIRIN BEER KK (Nakajima T, Matsunaga N): I-form crystal of N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N′-propylurea and process for producing the same. WO-03008388 (2003).
120. KIRIN BREWERY Co (Kubo K, Fujiwara Y Isoe T, Serizawa I): Quinolin derivative and pharmaceutical composition containing the same. JP-11158149 (1999).
121. KIRIN BEER KK (Fujiwara Y, Senga T, Nishiloba T, Osawa T, Miwa A): Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same. WO-03000660 (2003).
122. KIRIN BREWERYCO (Nakajima T, Kamimasahara M, Matsunaga N): N-(2-Chloro-4-{[6-methoxy-7-(3-pyridylmethoxy)-4-quinolyl]oxy}phenyl) -N′-propylurea dihydrochloride. JP-2002030083 (2002).
123. KIRIN BEER KK (Kubo K, Ohno H, Isoe T, Nishitoba T): Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor. WO-03093238 (2003).
124. EISAI Co LTD (Funahashi Y, Tsuruoka A, Matsukura M, Haneda T, Fukuda Y, Kamata J, Takahashi K, Matsushima T, Miyazaki K, Nomoto K Watanabe T et al): Nitrogenous aromatic ring compounds. WO-00232872 (2002).
125. EISAI Co LTD (Wakabayashi T, Ono N, Semba T, Haneda T): Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor. WO-03074045 (2003).
126. ASTRAZENECA AB (Baxter A, Brough S, Faull A, Johnstone C, McInally T): Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2. WO-00158890 (2001).
127. ASTRAZENECA AB (Faull A, Johnstone C, Morley A, Poyser JP): Novel compounds. WO-03010158 (2003).
128. ASTRAZENECA AB (Griffiths D, Johnstone C): Novel compounds. WO-03010163 (2003).
129. SMITHKLINE BEECHAM CORP (Callahan JF, Roshak AK): NF-κB inhibitors. WO-00230353 (2002).
130. SMITHKLINE BEECHAM CORP (Parrish CA, Callahan JF, Wan Z, Burgess JL, Stavenger RA, Holt DA): CHK 1 kinase inhibitors. WO-03028731 (2003).
131. SMITHKLINE BEECHAM CORP (Parrish CA, Callahan JF, Li Y, Stavenger RA, Holt DA): CHK 1 kinase inhibitors. WO-03029241 (2003).
132. SMITHKLINE BEECHAM CORP (Callahan JF, Li YH): NF-κB inhibitors. WO-03086309 (2003).
133. PHARMACIA CORP (Hagen TJ, Weier RM, Xu X, Houdek SC, Clare M): Substituted thiophene carboxamide compounds for the treatment of inflammation. WO-2004009582 (2004).
134. ICOS CORP (Keegan KS, Kesicki EA, Gaudino JJ, Cook AW, Cowen SD, Burgess LE): Aryl and heteroaryl urea CHK-1 inhibitors for use as radiosensitizers and chemosensitizers. WO-02070494 (2002).
135. MILLENNIUM PHARMACEUTICALS INC (Boyle RG, Imogai HJ, Cherry M): Diarylurea compounds and derivatives as CHK-1 inhibitors for the treatment of cancer. WO-03101444 (2003).
136. ABBOTT LABORATORIES (Li G, Li Q, Li T, Lin W, Mantei RA, Sham HL, Wang GT): Urea derivatives as kinase inhibitors. WO-2004014876 (2004).
137. BANYU PHARMACEUTICAL Co LTD (Hayama T, Hayashi K, Honma M, Takahashi I): Biarylurea derivatives. WO-00107411 (2001).
138. BANYU PHARMACEUTICAL Co LTD (Hatayama S, Hayashi K, Honma M, Takahashi I): CDK4 and/or CDK6 inhibitor including biarylurea compound or its salt as active ingredient. JP-2002220338 (2002).
139. AMGEN INC (Santora V, Askew BC, De Morin FF, Hague A, Laber E, Li A, Liu G, Lopez P, Nomak R, Tegley C, Yang K): Thiazolyl urea compounds for the treatment of cancer. WO-03070727 (2003).
140. MERCK & Co INC (Hartman GD, Tucker TJ, Sisko JT, Smith AM, Lumma WC Jr): Tyrosine kinase inhibitors. WO-03015717 (2003).
141. ASTRAZENECA AB (Berg S, Hellberg S): 4-(4-Methoxybenzyl)-N′-(5- nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (GSK3). WO-03004478 (2003).
142. PHARMACIA ITALIA SPA (Amici R, D'Anello M, Martina K, Salom B, Vulpetti A): Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them. WO-03028720 (2003).
143. CHIRON CORP (Renhowe PA, Ramurthy S, Amiri P, Levine BH, Poon DJ, Subramanian S, Sung L, Fantl W): Substituted benzazoles and use thereof as Raf kinase inhibitors. WO-03082272 (2003).
144. MERCK PATENT GMBH (Buchstaller HP, Weisner M, Schadt O, Amendt C, Zenke F, Sirrenberg C, Grell M): Glycinamide derivatives as Raf-kinase inhibitors. WO-2004019941 (2004).